N-[1(S)-(1(S)-benzylcarbamoyl-2-phenyl-ethylcarbamoyl)-2-methyl-propyl]-4-[(tert-butylcarbamoyl-methyl)-(5-guanidino-pentanoyl)-amino]-benzamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[1(S)-(1(S)-benzylcarbamoyl-2-phenyl-ethylcarbamoyl)-2-methyl-propyl]-4-[(tert-butylcarbamoyl-methyl)-(5-guanidino-pentanoyl)-amino]-benzamide
• 英文别名: N-[(S)-1-((S)-1-benzylcarbamoyl-2-phenyl-ethylcarbamoyl)-2-methyl-propyl]-4-[(tert-butylcarbamoyl-methyl)-(5-guanidino-pentanoyl)-amino]-benzamide；N-[(2S)-1-[[(2S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-4-[[2-(tert-butylamino)-2-oxoethyl]-[5-(diaminomethylideneamino)pentanoyl]amino]benzamide
• 化学式: C₄₀H₅₄N₈O₅
• 分子量: 726.919
• InChiKey: ZCTZZWVHSCBIPP-SHUZPENHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  53
• 可旋转键数：
  19
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  201
• 氢给体数：
  6
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-氨基颉草酸 在 lithium hydroxide 、 caesium carbonate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 达卡巴嗪 、 三乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 96.35h， 生成 N-[1(S)-(1(S)-benzylcarbamoyl-2-phenyl-ethylcarbamoyl)-2-methyl-propyl]-4-[(tert-butylcarbamoyl-methyl)-(5-guanidino-pentanoyl)-amino]-benzamide
  参考文献：
  名称：

  Modifications of the GSK3β substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics

  摘要：

  Amplification, overexpression, and elevated activation of Akt have been detected in many human malignancies making it an important target for cancer therapy. The Akt substrate-binding site offers a large number of potential interactions to an appropriately designed small molecule and can form the basis for the development of selective inhibitors. Here, we report the progression of GSK3 beta substrate-mimetic inhibitors towards the development of a potent, small molecule substrate-mimetic inhibitor of Akt. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.004

文献信息

• Modifications of the GSK3β substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics
  作者：Katherine J. Kayser、Matthew P. Glenn、Said M. Sebti、Jin Q. Cheng、Andrew D. Hamilton

  DOI：10.1016/j.bmcl.2007.01.004

  日期：2007.4

  Amplification, overexpression, and elevated activation of Akt have been detected in many human malignancies making it an important target for cancer therapy. The Akt substrate-binding site offers a large number of potential interactions to an appropriately designed small molecule and can form the basis for the development of selective inhibitors. Here, we report the progression of GSK3 beta substrate-mimetic inhibitors towards the development of a potent, small molecule substrate-mimetic inhibitor of Akt. (c) 2007 Elsevier Ltd. All rights reserved.